Blockchain Registration Transaction Record

Danish Biotech Lophora Initiates Phase 1 Trial of Novel Compound LPH-5 for CNS Disorders

Lophora, a Danish biotech, starts Phase 1 trial of novel compound LPH-5 targeting CNS disorders. With potential therapeutic benefits and non-hallucinogenic effects, this development could transform the treatment of neurological and psychiatric conditions.

Danish Biotech Lophora Initiates Phase 1 Trial of Novel Compound LPH-5 for CNS Disorders

This news highlights a significant milestone in the development of next-generation psychedelic therapies for CNS disorders. The advancement of LPH-5 by Lophora could potentially revolutionize the treatment landscape for conditions like depression and anxiety, offering hope for patients with treatment-resistant forms of these disorders.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0x034f0287171ef93ebc454bafe05df4aae7d3c59379e10aa00e13104cd5b4a73a
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintplumbKNI-944fe92ad8ff66ca7108cbd1406af95e